Department of Urology and Urosurgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Eur Urol Focus. 2021 Sep;7(5):1002-1010. doi: 10.1016/j.euf.2020.09.015. Epub 2020 Oct 24.
Focal therapy (FT) with its favorable side-effect profile represents an option between active surveillance and traditional whole-gland treatment in localized prostate cancer (PCa). Consensus statements recommend eligibility criteria based on magnetic resonance imaging (MRI)-targeted and systematic combination biopsy.
To estimate the future potential of FT by analyzing the number of men eligible for FT among all men with biopsy-proven PCa and to judge the potential of different energy sources.
DESIGN, SETTING, AND PARTICIPANTS: Consensus criteria on FT were analyzed. Patients with biopsy-proven PCa from six tertiary referral hospitals and one outpatient practice in Germany had received a software-based combination biopsy. Men with Prostate Imaging Reporting and Data System (PI-RADS) ≥3 lesions based on PI-RADS v2 were included.
Patients were analyzed for potential treatment by FT and hemiablation. MRI lesions were mapped according to prostatic zones.
In total, 2371 patients were analyzed. According to consensus criteria (biopsy-proven unifocal lesion of International Society of Urological Pathology [ISUP] grade group ≤2, prostate-specific antigen [PSA] ≤15ng/mL, and life expectancy >10yr), 303 patients (12.8%; ISUP 1: n=148 [6.2%]; ISUP 2: n=155 [6.5%]) were potential candidates for FT. A maximum PSA level of <10ng/mL would exclude further 60 (2.5%) of these men. The eligibility for hemiablation is slightly higher (16.2%). Unifocal lesions (n=288) were equally distributed within the prostate (anteriorly [31%], apically [29%], and dorsally [36%]).
With adherence to consensus statements, only a minority of PCa patients present as potential candidates for FT. Distribution of tumor localization suggests the need for different energy modalities to warrant an optimal FT treatment.
We analyzed how many men who receive a magnetic resonance imaging-targeted and systematic prostate biopsy are candidates for the experimental focal therapy of the prostate. When following expert recommendations, only a small number of men are potential candidates for this alternative treatment.
在局限性前列腺癌(PCa)中,局部治疗(FT)具有良好的副作用谱,是主动监测和传统全腺体治疗之间的一种选择。共识声明建议根据磁共振成像(MRI)靶向和系统联合活检来确定适合条件。
通过分析在所有经活检证实的 PCa 患者中适合 FT 的男性人数来估计 FT 的未来潜力,并判断不同能源的潜力。
设计、地点和参与者:分析了关于 FT 的共识标准。德国六家三级转诊医院和一家门诊诊所的经活检证实的 PCa 患者接受了基于软件的联合活检。纳入前列腺成像报告和数据系统(PI-RADS)v2 基于 PI-RADS≥3 病变的患者。
对 FT 和半切除治疗的潜在治疗进行了分析。根据前列腺区域对 MRI 病变进行了映射。
共分析了 2371 例患者。根据共识标准(经活检证实的国际泌尿病理学会[ISUP]分级组≤2 的单病灶、前列腺特异性抗原[PSA]≤15ng/mL 和预期寿命>10 年),303 例患者(12.8%;ISUP 1:n=148[6.2%];ISUP 2:n=155[6.5%])是 FT 的潜在候选者。最大 PSA 水平<10ng/mL 将进一步排除其中 60 例(2.5%)男性。半切除的适应证略高(16.2%)。单病灶(n=288)在前列腺内分布均匀(前[31%]、顶[29%]和背[36%])。
根据共识声明,只有少数 PCa 患者适合 FT。肿瘤定位分布表明需要不同的能源方式来保证最佳的 FT 治疗。
我们分析了在接受磁共振成像靶向和系统前列腺活检的患者中,有多少人是前列腺实验性局部治疗的候选者。当遵循专家建议时,只有少数男性是这种替代治疗的潜在候选者。